This article was originally published in The Gray Sheet
Executive SummaryLimited rollout of its cardioplagia safety system (CSS) for use during stopped-heart coronary artery bypass surgery commences following 510(k) clearance May 4, the firm reports. The device "controls potassium flow level and dilution, monitors flow pressure and guards against air in the line" after blood flow through the aorta is stopped and potassium is delivered to arrest the heartbeat, Medtronic says in a May 12 release. The CSS features reduce the incidence of accidental vessel rupture due to over pressurization, the firm claims...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.